Table 2.
Most common adverse reactions associated with the usage of ceritinib
| All grades (%) | Grades 3–4 (%) | Dose reduction or discontinuation (%) | |
|---|---|---|---|
| Most common clinical adverse reaction | |||
| Diarrhea | 86 | 6 | 16 |
| Nausea | 80 | 4 | 20 |
| Vomiting | 60 | 4 | 16 |
| Abdominal pain | 54 | 2 | |
| Fatigue | 52 | 5 | |
| Decreased appetite | 34 | 1 | |
| Constipation | 29 | 0 | |
| Most common laboratory adverse reaction | |||
| Decreased Hg | 84 | 5 | |
| Increased ALT | 80 | 27 | 29 |
| Increased AST | 75 | 13 | 16 |
| Increased creatinine | 58 | 2 | |
| Hyperglycemia | 49 | 13 | |
| Hypophosphatemia | 36 | 7 | |
| Increased lipase | 29 | 10 | |
| Less common clinical and laboratory adverse reactions | |||
| Neuropathy | 17 | ||
| Vision disturbances | 9 | ||
| Prolonged QT interval | 4 | ||
| Bradycardia | 3 | ||
| ILD/pneumonitis | 4 | 3 | |
| Increased bilirubin | 15 | 1 | |
| Rash | 16 | 0 | |